Current Clinical Practice: High-Dose Chemotherapy and Stem Cell Transplantation for Non-Hodgkin's Lymphoma: Review of Recent Advances

References

• Gratwohl, A., Passweg, J., Baldomero, H. and Hermans, J. (1999). Blood, and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow, Transplantation (EBMT). Bone Marrow Transplant, 24(3), 145–231.
   Web of Science ®Google Scholar
• Bociek, G., Bierman, P., Lynch, J., et al. (1999). High-Dose Therapy with Autologous Hematopoietic Stem Cell Transplantation for Follicular Non-Hodgkin's Lymphoma: Long Term Results. Abstract # 8 ASCO.
   Google Scholar
• Brice, P., Simon, D., Bouabdallah, R., et al. (1998). Autologous Stem Cell Transplantation (ASCT) Improves Survival after Progression for Patiens with a Follicular Lymphoma (GELF 86 Protocols). Abstract # 1913 ASH.
   Google Scholar
• Conde, E., Lahuerta, J., Sierra, J., et al. (1998). Autologous Stem Cell Transplantation (ASCT) for Follicular Lymphoma (FL). The Experience of the GEL/TAMO Spanish Cooperative Group. Abstract # 1914 ASH.
   Google Scholar
• Schouten, H. C., Bierman, P. J., William, P., et al. (1989). Autologous Bone Marrow Transplantation in Follicular Non-Hodgkin's Lymphoma Before and After Histologic Transformation. Blood, Nov 15; 74(7), 2579–2584.
   PubMed Web of Science ®Google Scholar
• Friedberg, J., Neuberg, D., Gribben, J., et al. (1998). Autologous Bone Marrow Transplantation Following Histologic Transformation of Indolent B Cell Non-Hodgkin's Lymphoma. Abstract # 2982 ASH.
   Google Scholar
• Foran, J. M., Apostolidis, J., Papamichael, D., et al. (1998). High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: A study of 27 patients form a single centre. Ann Oncol, 9, 865–869.
   PubMed Web of Science ®Google Scholar
• Rabinowe, S. N., Soiffer, R. J., Gribben, J. G., et al. (1993). Autologous and Allogeneic Bone Marrow Transplantation for Poor Prognosis Patients With B-Cell Chronic Lymphocytic Leukemia. Blood, Aug 15; 82(4), 1366–1376.
   PubMed Web of Science ®Google Scholar
• Pavletic, Z. S., Bierman, P., Vose, J., et al. (1997). Long-term outcome of autologous stem cell transplantation for chronic lymphocytic leukemia or small lymphocytic lymphoma (B-CLL). Abstract # 1032 ASH.
   Google Scholar
• Esteve, J., Villamor, N., Colomer, D., et al. (1998). Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. Ann Oncol, Feb; 9(2), 167–172.
   PubMed Web of Science ®Google Scholar
• Dreger, P., von Neuhoff, N., Kuse, R., et al. (1998). Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer, Jun; 77(12), 2291–2297.
   PubMed Web of Science ®Google Scholar
• Scime, R., Indovina, A., Santoro, A., et al. (1998). PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Bone Marrow Transplant, Dec; 22(12), 1159–1165.
   PubMed Web of Science ®Google Scholar
• Corradini, P., Astolfi, M., Voena, C., et al. (1998). High-Dose Chemotherapy and PBPC Autografting Induce Durable Molecular Remissions in Follicular Lymphomas, but not in Small Lymphocytic and Mantle Cell Lymphomas. Abstract # 1912 ASH.
   Google Scholar
• Andersen, N. S., Donovan, J. W., Borus, J. S., et al. (1997). Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood, Nov 15; 90(10), 4212–4221.
   PubMed Web of Science ®Google Scholar
• Conde, E., Bosch, F., Arranz, R., et al. (1998). Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL). The Experience of the GEL/TAMO Spanish Cooperative Group. Abstract # 1915 ASH.
   Google Scholar
• Khouri, I., Romaguera, J., Hagop, K., et al. (1998). Hyper-CVAD and High-Dose Methotrexate/Cytarabine Followed by Stem Cell Transplantation: An Active Regimen for Aggressive Mantle-Cell Lymphoma. J Clin Oncol, Dec; 16(12), 3803–3809.
   PubMed Web of Science ®Google Scholar
• Milpied, N., Gaillard, F., Moreau, P., et al. (1998). High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant, 22, 645–650.
   PubMed Web of Science ®Google Scholar
• Gianni, A. M., Bregni, M., Siena, S., et al. (1997). High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma. N Engl J Med, May 1; 336(18), 1290–1297.
   PubMed Web of Science ®Google Scholar
• Santini, G., Salvagno, L., Leoni, P., et al. (1998). VACOP-B Versus VACOP-B Plus Autologous Bone Marrow Transplantation for Advanced Diffuse Non-Hodgkin's Lymphoma: Results of a Prospective Randomized Trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol, Aug; 16(8), 2796–2802.
   PubMed Web of Science ®Google Scholar
• Haioun, C., Lepage, E., Gisselbrecht, C., et al. (1994). Comparison of Autologous Bone Marrow Transplantation With Sequential Chemotherapy for Intermediate-Grade and High-Grade Non-Hodgkin's Lymphoma in First Complete Remission: A Study of 464 Patients. J Clin Oncol, Dec; 12(12), 2543–2551.
   PubMed Web of Science ®Google Scholar
• Haioun, C., Lepage, E., Gisselbrecht, C., et al. (1997). Benefit of Autologous Bone Marrow Transplantation Over Sequential Chemotherapy in Poor-Risk Aggressive Non-Hodgkin's Lymphoma: Updated Results of the Prospective Study NHL 872. Groupe d'Etude des Lymphomes de I'Adulte. J Clin Oncol, Mar; 15(3), 1131–1137.
   PubMed Web of Science ®Google Scholar
• Verdonck, L. F., van Putten, W. L. J., Hagenbeek, A., et al. (1995). Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin's Lymphoma. N Engl JMed, 332(16), 1045–1051.
   PubMed Web of Science ®Google Scholar
• Martelli, M., Vignetti, M., Zinzani, P. L., et al. (1996). High-Dose Chemotherapy Followed by Autologous Bone Marrow Transplantation Versus Dexamethasone, Cisplatin, and Cytarabine in Aggressive Non-Hodgkin's Lymphoma With Partial Response to Front-Line Chemotherapy: A Prospective Randomized Italian Multicenter Study. J Clin Oncol, Feb; 14(2), 534–542.
   PubMed Web of Science ®Google Scholar
• Philip, T., Guglielmi, C., Hagenbeek, A., et al. (1995). Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma. N Engl J Med, Dec 7; 333(23), 1540–1545.
   PubMed Web of Science ®Google Scholar
• Shipp, M. A., Abeloff, M. D., Antman, K. H., et al. (1999). International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury. J Clin Oncol, January; 17(1), 423–429.
   PubMed Web of Science ®Google Scholar
• Gribben, J. G., Neuberg, D., Barber, M., et al. (1994). Detection of Residual Lymphoma Cells by Polymerase Chain Reaction in Peripheral Blood Is Significantly Less Predictive for Relapse Than Detection in Bone Marrow. Blood, Jun 15; 83(12), 3800–3807.
   PubMed Web of Science ®Google Scholar
• Léonard, B. M., Hétu, F., Busque, L., et al. (1998). Lymphoma Cell Burden in Progenitor Cell Grafts Measured by Competitive Polymerase Chain Reaction: Less Than One Log Difference Between Bone Marrow and Peripheral Blood Sources. Blood, January 1; 91(1), 331–339.
   PubMed Web of Science ®Google Scholar
• Demirkazik, A., Armitage, J. O., Bierman, P. J., et al. (1998). Factors Affecting Progenitor Cell and Tumor Cell Content of Blood Stem Cell Harvests of Lymphoma Patients. Abstract # 480 ASH.
   Google Scholar
• Jacquy, C., Soree, A., Bosly, A., et al. (1998). Peripheral Blood Stem Cells Contamination in Diffuse Large Cell (DLCL) and Mantle Cell (MCL) Lymphomas: A Quantitative Comparison. Abstract # 976 ASH.
   Google Scholar
• Gribben, J. G., Saporito, L., Barber, M., et al. (1992). Bone Marrows of Non-Hodgkin's Lymphoma Patients With a bcl-2 Translocation Can Be Purged of Polymerase Chain Reaction-Detectable Lymphoma Cells Using Monoclonal Antibodies and Immunomagnetic Bead Depletion. Blood, Aug 15; 80(4), 1083–1089.
   PubMed Web of Science ®Google Scholar
• Mc Cann, J. C., Kanteti, R., Shilepsky, B., et al. (1996). High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation, 2, 37–43.
   PubMedGoogle Scholar
• Damiani, D., Fanin, R., Silvestri, F., et al. (1997). Randomized Trial of Autologous Filgastrim-Primed Bone Marrow Transplantation Versus Filgastrim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma Patients. Blood, July 1; 90(1), 36–42.
   PubMed Web of Science ®Google Scholar
• Majolino, I., Pearce, R., Taghipour, G., et al. (1997). Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol, Feb; 15(2), 509–17.
   PubMed Web of Science ®Google Scholar
• Brunvand, M. W., Bensinger, W. I., Soll, E., et al. (1996). High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. Bone Marrow Transplant, Jul; 18(1), 131–41.
   PubMed Web of Science ®Google Scholar
• Sharp, J. G., Kessinger, A., Mann, S., et al. (1996). Outcome of High-Dose Therapy and Autologous Transplantation in Non-Hodgkin's Lymphoma Based on the Presence of Tumor in the Marrow or Infused Hematopoietic Harvest. J Clin Oncol, January; 14(1), 214–219.
   PubMed Web of Science ®Google Scholar
• Moos, M., Schulz, R., Murea, S., et al. (1997). Monitoring of minimal disease in patients with follicular non-Hodgkin's lymphoma undergoing high-dose therapy with peripheral blood stem cell support. Abstract # 340 ASH.
   Google Scholar
• Pappa, V. I., Wilkes, S., Salam, A., et al. (1998). Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t (14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment. Bone Marrow Transplant, 22, 553–558.
   PubMed Web of Science ®Google Scholar
• Bird, J. M., Luger, S., Mangan, P., et al. (1996). 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients all high risk of bone marrow involvement. Bone Marrow Transplant, Aug; 18(2), 309–313.
   PubMed Web of Science ®Google Scholar
• Miller, C. B., Jones, R. J., Piantadosi, S., et al. (1998). Analysis of Engraftment in a Randomized Trial of 4 Hydroperoxycyclophosphamide (4HC) Purged Autologous Bone Marrow Transplant (ABMT) in Patients with Lymphoid Malignancies: Preliminary Analysis of Engraftment. Abstract # 1897 ASH.
   Google Scholar
• Straka, C., Oduncu, F., Drexler, E., et al. (1998). Monoclonal B-Cells in PBSC Autografts after Immunomagnetic B-Cell Purging Predict a Shorter Freedom from Progression in Low-Grade Lymphoma. Abstract # 2024 ASH.
   Google Scholar
• Tarella, C., Ferrero, D., Corradini, P., et al. (1998). Feasibility and efficacy of negative in vitro purging on mobilized hemopoietic progenitors in follicular and mantle cell lymphoma patients treated with the HDS regimen. Abstract # 954 ASH.
   Google Scholar
• Apostolidis, J., Gupta, R. K., Johnson, P. W. M., Morresey, K., Ledchumykanthan, K., Lister, T. A. and Rohatiner, A. Z. S. (1997). Molecular follow up of patients consolidated with myeloablative therapy and autologous bone marrow support for follicular lymphoma. Proc Am Soc Hematol, abstract # 502.
   Google Scholar
• Apostolis, J., Gupta, R. K., Summers, K., et al. (1997). Concentrated CD34+ cells derived from the blood to support myeloablative therapy in patients with follicular lymphoma. Abstract # 4321 ASH.
   Google Scholar
• Vescio, R., Schiller, G., Stewart, A. K., Ballester, O., Noga, S., Rugo, H., Freytes, C., Stadtmauer, E., Tarantolo, S., Sahebi, F., Stiff, P., Meharchard, J., Schlossman, R., Brown, R., Tully, H., Benyunes, M., Jacobs, C., Berenson, R., DiPersio, J., Anderson, K. and Berenson, J. (1999). Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous periheral blood progenitor cell transplantation in multiple myeloma. Blood, 93, 1858–1868.
   PubMed Web of Science ®Google Scholar
• Bruno, A., Adorno, G., Del Poeta, G., Venditti, A., Ballatore, G., Zinno, F., Lanti, A., Buccisano, F., Tamburini, A., Caravita, T., Santinelli, S., Maurillo, L., Aronica, G., Masi, M., Isacchi, G. and Amadori, S. (1998). Analysis of parameters influencing the positive selection of peripheral blood progenitor cells in patients with hematological malignancies and solid tumors. Abstract # 1822 ASH.
   Google Scholar
• Voso, M. T., Hohaus, S., Pforsich, M., et al. (1998). Auto-grafting with selected CD34+ cells: retained engraftment capability and reduced tumor cell content. Abstract # 2407 ASH.
   Google Scholar
• Gorin, N. C., Lopez, M., Laporte, J. P. H., et al. (1995). Preparation and Successful Engraftment of Purified CD34+ Bone Marrow Progenitor Cells in Patients With Non-Hodgkin's Lymphoma. Blood, Mar 15; 85(6), 1647–1654.
   PubMed Web of Science ®Google Scholar
• Macintyre, E. A., Belanger, C., Debert, C., et al. (1995). Detection of Clonal CD34+ 19+ Progenitors in Bone Marrow of BCL 2-lg H—Positive Follicular Lymphoma Patients. Blood, Dec 15; 86(12), 4691–4698.
   PubMed Web of Science ®Google Scholar
• Noack, B., Mucke, C., Reufi, B., et al. (1998). Double Purging of Autografts in B-Cell Malignancies. Abstract # 1837 ASH.
   Google Scholar
• Paulus, U., Schmitz, N., Viekmann, K., et al. (1997). Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant, Sep; 20(5), 415–420.
   PubMed Web of Science ®Google Scholar
• Vose, J., Bierman, P. J., Atkinson, K., Lynch, J. C., Juttner, C., Hanania, E., Reading, C., Ramanathan, R. and Armitage, J. O. 1998. (1998). Transplantation following high-dose chemo and CD34+TFIY1+/LIN- peripheral blood stem cells (PBSC) in patients (pts) with non-Hodgkin's lymphoma (NHL). Abstract # 2979 ASH.
   Google Scholar
• Williams, C. D., Goldstone, A. H., Pearce, R. M., et al. (1996). Purging of Bone Marrow in Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma: A Case-Matched Comparison With Unpurged Cases by the European Blood and Marrow Transplant Lymphoma Registry. Journal of Clinical Oncology, September; 14(9), 2454–2464.
   PubMed Web of Science ®Google Scholar
• Tarella, C., Caracciolo, D., Corradini, P., et al. (1998). Combined High-Dose Mitoxantrone and L-Pam as Conditioning Regimen for Autograft in 93 Lymphoma Patients: High Tolerability, Low and Reversible Cardiotoxicity. Abstract # 521 ASH.
   Google Scholar
• Jerjis, S. H., Roovers, E., Muus, P., et al. (1998). Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remision. Bone Marrow Transplant, 22, 13–19.
   PubMed Web of Science ®Google Scholar
• Cocorocchio, E., Peccatori, F., El Taani, H., et al. (1998). Idarubicin and Melphalan as Myeloablative Regimen after Sequential High Dose Chemotherapy for Lymphomas: Preliminary Results of a Phase I-II Study with Pharmacokinetical Guided Peripheral Blood Progenitor Cell Reinfusion. Abstract # 4230 ASH.
   Google Scholar
• Liu, S. Y., Eary, J. F., Petersdorf, S. H., et al. Follow-up of Relapsed B-Cell Lymphoma Patients Treated With Iodine-131-Labeled Anti-CD20 Antibody and Autologous Stem-Cell Rescue. J Clin Oncol, 16, 3270–3278.
   PubMed Web of Science ®Google Scholar
• Gopal, A., Eary, J., Maloney, S., et al. (1999). High Dose Radioiodinated Anti-CD20 Antibody, Etoposide, Cyclophosphamide and Autologous Transplantation for Patients with Relapsed or Refractory Mantle Cell Lymphoma. Abstract # 54 ASCO.
   Google Scholar
• Tsai, D. E., Moore, H. C. F., Porter, D. L., et al. (1998). Progressive Intermediate Grade Non-Hodgkin's Lymphoma after High Dose Therapy and Autologous Peripheral Stem Cell Transplantation (PSCT) has a High Response Rate to Rituximab. Abstract # 1713 ASH.
   Google Scholar
• Buckstein, R., Imrie, K., Spaner, D., et al. (1998). The Effects of in Vivo Purging with Rituxan on Stem Cell Mobilization Efficacy, Harvest Purity, Cytokine Profile and Engraftment in Patients with Relapsed Follicular Lymphoma Undergoing Autologous Stem Cell Transplant. Abstract # 2672 ASH.
   Google Scholar
• Flinn, I. W., O'Donnell, P., Noga, S.J., et al. (1998). In Vivo Purging and Adjuvant Immunotherapy with Rituximab during PBSC Transplant for NHM. Abstract # 2673 ASH.
   Google Scholar
• Ballester, O. F., Wilcox, P., Musick, R., et al. (1998). Rituximab can be safely included as part of High-Dose Therapy/Autologous Stem Cell Transplantation for Patients with Non-Hodgkin's Lymphoma. Abstract # 4552 ASH.
   Google Scholar
• Peniket, A. J., Ruiz de Elvira, M. C., Taghipour, G., et al. (1997). Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival has not risen because of higher treatment-related mortality—a report of 764 cases from the EBMT lymphoma registry. Abstract # 1121 ASH.
   Google Scholar
• Schimmer, A., Jamal, S., Smith, A., et al. (1998). Results of a Provincial Strategy for Allogeneic or Autologous Bone Marrow Transplantation (BMT) as Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL). Abstract # 1174 ASH.
   Google Scholar
• Karanes, C., Du, W., Abella, E., et al. (1998). Single Institution Cohort Analysis of Allogeneic and Autologous Stem Cell Transplantation for Non-Hodgkins Lymphoma. Abstract # 1172 ASH.
   Google Scholar
• Ratanatharathorn, V., Uberti, J., Karanes, C. H., et al. (1994). Prospective Comparative Trial of Autologous Versus Allogeneic Bone Marrow Transplantation in Patients With Non-Hodgkin's Lymphoma. Blood, Aug 15; 84(4), 1050–1055.
   PubMed Web of Science ®Google Scholar
• Attal, M., Socié, G., Molina, L., et al. (1997). Allogeneic bone marrow transplantation for refractory and recurrent follicular lymphoma: a case-matched analysis with autologous transplantation from the french bone marrow transplantation group registry data. Abstract # 1120 ASH.
   Google Scholar
• Van Besien, K., Sobocinski, K., Rowlings, P. H., et al. (1998). Allegeneic Bone Marrow Transplantation for Low-Grade Lymphoma. Blood Sep 1; 92(5), 1832–1836.
   PubMed Web of Science ®Google Scholar
• Khouri, I., Mirza, N., Przepiorka, D., et al. (1998). Histology Subtype Predicts Outcome of Allegeneic Transplantation for Low Grade Lymphoma. Abstract # 1176 ASH.
   Google Scholar
• Molina, A., Nademanee, A., O'Donnell, M. R., et al. (1998). Autologous (auto) and Allogeneic (allo) Stem Cell Transplantation (SCT) for Poor-Risk Mantle Cell Lymphoma (MCL): The City of Hope (COH) Experience. Abstract # 1894 ASH.
   Google Scholar
• Sohn, S. K., Bensinger, W., Holmberg, L., et al. (1998). High Dose Therapy with Allogeneic or Autologous Stem Cell Transplantation for Relapsed Mantle Cell Lymphoma: The Seattle Experience. Abstract # 64 ASCO.
   Google Scholar
• Gribben, J. G., Neuberg, D., Soiffer, R. J., et al. (1998). Autologous Versus Allogeneic Bone Marrow Transplantation for Patients with Poor Prognosis CLL. Abstract # 1320 ASH.
   Google Scholar
• Dhedin, N., Giraudier, S., Esperou, H., et al. (1997). Allogeneic bone marrow transplantation for aggresive non-Hodgkin's lymphoma (except lymphoblastic and Burkitt): a report of the French Registry C. Abstract # 4487 ASH.
   Google Scholar
• Sweetenham, J. W., Bierman, P., Taghipour, G., et al. (1997). Two-thirds of adult patients with lymphoma achieve long-term survival after syngeneic bone marrow transplantation—results from the EBMT. Abstract # 4512 ASH.
   Google Scholar
• Bierman, P., Molina, A., Nelson, G., et al. (1999). Matched Unrelated Donor (MUD) Allogeneic Bone Marrow Transplantation for Non-Hodgkin's Lymphoma (NHL): Results from the National Marrow Donor Program (NMDP). Volume 18 ASCO.
   Google Scholar
• Bierman, P., Kottaridis, P., Kollath, J., et al. (1998). Allogeneic Transplantation Following Failure of Autologous Transplantation for Lymphoma. Abstract # 1315 ASH.
   Google Scholar
• Radich, J. P., Gooley, T., Sanders, J. E., et al. (1998). Second Allogeneic Transplants after Failure of Autologous First Transplant. Abstract # 2034 ASH.
   Google Scholar
• McQuaker, I. G., Haynes, A. P., Carter, G. I., et al. (1998). α-interferon can reinduce molecular remission in patients with molecular relapse after high-dose therapy for follicular lymphoma. Abstract # 4466 ASH.
   Google Scholar
• Schenkein, D. P., Dixon, P., Desforges, J. F., et al. (1994). Phase I/II Study of Cyclophosphamide, Carboplatin and Etoposide and Autologous Hematopoietic Stem-Cell Transplantation with Post-transplant Interferon Alfa-2b for Patients with Lymphoma and Hodgkin's Disease. J Clin Oncol, 12(11), 2423–2431.
   PubMed Web of Science ®Google Scholar
• Gryn, J., Johnson, E., Goldman, N., Devereux, L., Grana, G., Hageboutros, A., Fernandez, E., Constantinou, C., Harrer, W., Viner, E. and Goldberg, J. (1997). The treatment of relapsed or refraactory intermediate grade lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplant, 19, 221–226.
   PubMed Web of Science ®Google Scholar
• Gryn, J., Goldberg, J., Hageboutros, A., et al. (1997). Lack of autologous graft-versus-host disease following peripheral blood stem cell transplants for non-Hodgkin's lymphoma. Abstract # 4185 ASH.
   Google Scholar
• Massumoto, C., Benyunes, M. C., Sale, G., et al. (1996). Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant, Mar; 17(3), 351–356.
   PubMed Web of Science ®Google Scholar
• Fefer, A., Robinson, N., Benyunes, M. C., et al. (1997). Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. Cancer J Sci Am, Dec; 3(1), S 48–53.
   Google Scholar
• Robinson, N., Benyunes, M. C., Thompson, J. A., et al. (1997). Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplant, 19(5), 435–442.
   PubMed Web of Science ®Google Scholar
• Van Besien, K., Margolin, K., Champlin, R., et al. (1997). Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer J Sci Am, Dec; 3(1), S54–8.
   PubMedGoogle Scholar
• Slavin, S. and Nagler, A. (1998). Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. Ann Oncol, 9(1), S31–9.
   PubMedGoogle Scholar
• Kwak, L. W., Campbell, M. J., Czerwinski, D. K., et al. (1992). Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by their Tumors. N Engl J Med, Oct 22;327(17), 1209–1215.
   PubMed Web of Science ®Google Scholar
• Bendandi, M., Gocke, C., Kobrin, C., et al. (1998). Molecular Complete Remissions Induced by Patient-Specific Vaccination in Most Patients with Follicular Lymphoma (FL). Abstract # 616 ASH.
   Google Scholar
• Davis, T. A., Hsu, F. J., Caspar, C. B., et al. (1999). Idiotype Vaccination Following ABMT Can Stimulate Specific Anti-Idiotype Immune Responses in Patients With B Cell Lymphoma (B-NHL). Abstract # 9 ASCO.
   Google Scholar
• Timmerman, J., Davis, T., Hsu, F., et al. (1999). Clinical Trials of Idiotype Vaccination for B-Cell Lymphoma: Qualitative Differences in Anti-Idiotypic Immune Responses Using Dendritic Cells Versus QS-21-Based Chemical Adjuvants. Abstract # 1670 ASCO.
   Google Scholar
• Borrello, I., Sotomayor, E. M., Cooke, S., et al. (1998). Description of a Universal GM-CSF-Producing Bystander Cell for Use in Autologous Tumor Cell Vaccine Formulations. Abstract # 1007 ASH.
   Google Scholar
• Porter, D. L., Connors, J. M., Van Deerlin, V. M. D., et al. (1999). Graft-Versus-Tumor Induction With Donor Leukocyte Infusions as Primary Therapy for Patients With Malignancies. J Clin Oncol, April; 17(4), 1234–1243.
   PubMed Web of Science ®Google Scholar
• Varadi, G., Or, R., Kapelushnik, J., et al. (1999). Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma, Jun; 34(1–2), 185–190.
   PubMed Web of Science ®Google Scholar
• Khouri, I. F., Keating, M., Korbling, M., et al. Transplant-Lite: Induction of Graft-Versus-Malignancy Using Fludarabine-Based Nonablative Chemotherapy and Allogeneic Blood Progenitor-Cell Transplantation as Treatment for Lymphoid Malignancies. J Clin Oncol, 16, 2817–2824.
   PubMed Web of Science ®Google Scholar
• Childs, R., Bahceci, E., Clave, E., et al. (1998). Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplants (PBSCT) for Malignant Diseases Reduces Transplant-Related Mortality (TRM). Abstract # 552 ASH.
   Google Scholar
• Sykes, M., Preffer, F., McAfee, S., et al. (1999). Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. The Lancet, May 22; 353, 1755–1759.
   PubMed Web of Science ®Google Scholar
• Guinan, E. C., Boussiotis, V. A., Neuberg, D., et al. (1999). Transplantation of Anergic Histoincompatible Bone Marrow Allografts. N Engl J Med, June 3; 340(22), 1704–1714.
   PubMed Web of Science ®Google Scholar